|
1
|
Akerström F, Barderas MG and
Rodríguez-Padial L: Aortic stenosis: A general overview of
clinical, pathophysiological and therapeutic aspects. Expert Rev
Cardiovasc Ther. 11:239–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bossé Y, Mathieu P and Pibarot P:
Genomics: The next step to elucidate the etiology of calcific
aortic valve stenosis. J Am Coll Cardiol. 51:1327–1336. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wypasek E, Potaczek DP and Undas A:
Association of the C-reactive protein gene (CRP) rs1205 C>T
polymorphism with aortic valve calcification in patients with
aortic stenosis. Int J Mol Sci. 16:23745–23759. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coffey S, Cox B and Williams MJA: The
prevalence, incidence, progression, and risks of aortic valve
sclerosis: A systematic review and meta-analysis. J Am Coll
Cardiol. 63:2852–2861. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carabello BA: Aortic stenosis: A fatal
disease with but a single cure. JACC Cardiovasc Interv. 1:127–128.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Novaro GM and Griffin BP: Calcific aortic
stenosis: Another face of atherosclerosis? Cleve Clin J Med.
70:471–477. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fondard O, Detaint D, Iung B, Choqueux C,
Adle-Biassette H, Jarraya M, Hvass U, Couetil JP, Henin D, Michel
JB, et al: Extracellular matrix remodelling in human aortic valve
disease: The role of matrix metalloproteinases and their tissue
inhibitors. Eur Heart J. 26:1333–1341. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galante A, Pietroiusti A, Vellini M,
Piccolo P, Possati G, De Bonis M, Grillo RL, Fontana C and Favalli
C: C-reactive protein is increased in patients with degenerative
aortic valvular stenosis. J Am Coll Cardiol. 38:1078–1082. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fayad ZA, Mani V, Woodward M, Kallend D,
Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, et
al: dal-PLAQUE Investigators: Safety and efficacy of dalcetrapib on
atherosclerotic disease using novel non-invasive multimodality
imaging (dal-PLAQUE): A randomised clinical trial. Lancet.
378:1547–1559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duvic M, Nagpal S, Asano AT and
Chandraratna RAS: Molecular mechanisms of tazarotene action in
psoriasis. J Am Acad Dermatol. 37:S18–S24. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roh SG, Song S-H, Choi K-C, Katoh K,
Wittamer V, Parmentier M and Sasaki S: Chemerin-a new adipokine
that modulates adipogenesis via its own receptor. Biochem Biophys
Res Commun. 362:1013–1018. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wittamer V, Franssen J-D, Vulcano M,
Mirjolet J-F, Le Poul E, Migeotte I, Brézillon S, Tyldesley R,
Blanpain C, Detheux M, et al: Specific recruitment of
antigen-presenting cells by chemerin, a novel processed ligand from
human inflammatory fluids. J Exp Med. 198:977–985. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Döcke S, Lock JF, Birkenfeld AL, Hoppe S,
Lieske S, Rieger A, Raschzok N, Sauer IM, Florian S, Osterhoff MA,
et al: Elevated hepatic chemerin mRNA expression in human
non-alcoholic fatty liver disease. Eur J Endocrinol. 169:547–557.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weigert J, Neumeier M, Wanninger J,
Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schäffler A,
Aslanidis C, et al: Systemic chemerin is related to inflammation
rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf).
72:342–348. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rourke JL, Dranse HJ and Sinal CJ: Towards
an integrative approach to understanding the role of chemerin in
human health and disease. Obes Rev. 14:245–262. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lehrke M, Becker A, Greif M, Stark R,
Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker
C, et al: Chemerin is associated with markers of inflammation and
components of the metabolic syndrome but does not predict coronary
atherosclerosis. Eur J Endocrinol. 161:339–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisinger K, Krautbauer S, Wiest R, Weiss
TS and Buechler C: Reduced serum chemerin in patients with more
severe liver cirrhosis. Exp Mol Pathol. 98:208–213. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gu P, Jiang W, Lu B and Shi Z: Chemerin is
associated with inflammatory markers and metabolic syndrome
phenotypes in hypertension patients. Clin Exp Hypertens.
36:326–332. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kostopoulos CG, Spiroglou SG, Varakis JN,
Apostolakis E and Papadaki HH: Chemerin and CMKLR1 expression in
human arteries and periadventitial fat: A possible role for local
chemerin in atherosclerosis? BMC Cardiovasc Disord. 14:562014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goralski KB, McCarthy TC, Hanniman EA,
Zabel BA, Butcher EC, Parlee SD, Muruganandan S and Sinal CJ:
Chemerin, a novel adipokine that regulates adipogenesis and
adipocyte metabolism. J Biol Chem. 282:28175–28188. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bondue B, De Henau O, Luangsay S, Devosse
T, de Nadaï P, Springael JY, Parmentier M and Vosters O: The
chemerin/ChemR23 system does not affect the pro-inflammatory
response of mouse and human macrophages ex vivo. PLoS One.
7:e400432012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bondue B, Wittamer V and Parmentier M:
Chemerin and its receptors in leukocyte trafficking, inflammation
and metabolism. Cytokine Growth Factor Rev. 22:331–338. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ernst MC and Sinal CJ: Chemerin: At the
crossroads of inflammation and obesity. Trends Endocrinol Metab.
21:660–667. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hart R and Greaves DR: Chemerin
contributes to inflammation by promoting macrophage adhesion to
VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J
Immunol. 185:3728–3739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaur J, Adya R, Tan BK, Chen J and Randeva
HS: Identification of chemerin receptor (ChemR23) in human
endothelial cells: Chemerin-induced endothelial angiogenesis.
Biochem Biophys Res Commun. 391:1762–1768. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Monnier J, Lewén S, O'Hara E, Huang K, Tu
H, Butcher EC and Zabel BA: Expression, regulation, and function of
atypical chemerin receptor CCRL2 on endothelial cells. J Immunol.
189:956–967. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao RJ and Wang H: Chemerin/ChemR23
signaling axis is involved in the endothelial protection by K(ATP)
channel opener iptakalim. Acta Pharmacol Sin. 32:573–580. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kukla M, Zwirska-Korczala K, Gabriel A,
Waluga M, Warakomska I, Szczygiel B, Berdowska A, Mazur W,
Wozniak-Grygiel E and Kryczka W: Chemerin, vaspin and insulin
resistance in chronic hepatitis C. J Viral Hepat. 17:661–667.
2010.PubMed/NCBI
|
|
29
|
Cash JL, Hart R, Russ A, Dixon JPC,
Colledge WH, Doran J, Hendrick AG, Carlton MB and Greaves DR:
Synthetic chemerin-derived peptides suppress inflammation through
ChemR23. J Exp Med. 205:767–775. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mariani F and Roncucci L: Chemerin/chemR23
axis in inflammation onset and resolution. Inflamm Res. 64:85–95.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Semba RD, Crasto C, Strait J, Sun K,
Schaumberg DA and Ferrucci L: Elevated serum fibroblast growth
factor 21 is associated with hypertension in community-dwelling
adults. J Hum Hypertens. 27:397–399. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
van de Voorde J, Pauwels B, Boydens C and
Decaluwé K: Adipocytokines in relation to cardiovascular disease.
Metabolism. 62:1513–1521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang X, Yeung DCY, Karpisek M, Stejskal
D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, et al: Serum
FGF21 levels are increased in obesity and are independently
associated with the metabolic syndrome in humans. Diabetes.
57:1246–1253. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
An SY, Lee MS, Yi SA, Ha ES, Han SJ, Kim
HJ, Kim DJ and Lee KW: Serum fibroblast growth factor 21 was
elevated in subjects with type 2 diabetes mellitus and was
associated with the presence of carotid artery plaques. Diabetes
Res Clin Pract. 96:196–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chow WS, Xu A, Woo YC, Tso AWK, Cheung
SCW, Fong CHY, Tse HF, Chau MT, Cheung BM and Lam KS: Serum
fibroblast growth factor-21 levels are associated with carotid
atherosclerosis independent of established cardiovascular risk
factors. Arterioscler Thromb Vasc Biol. 33:2454–2459. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S,
Xiao J, Wang X, Feng W and Li X: Serum levels of FGF-21 are
increased in coronary heart disease patients and are independently
associated with adverse lipid profile. PLoS One. 5:e155342010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu P, Zhang Y, Liu Y, Yuan Q, Song L, Liu
M, Liu Z, Yang Y, Li J, Li D, et al: Fibroblast growth factor 21
attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB
signaling pathways. Toxicol Appl Pharmacol. 290:43–53. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Han X, Chen C, Cheng G, Xie C, Yang M,
Shou X and Sun C: Serum fibroblast growth factor 21 levels are
increased in atrial fibrillation patients. Cytokine. 73:176–180.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Itoh N and Ornitz DM: Fibroblast growth
factors: From molecular evolution to roles in development,
metabolism and disease. J Biochem. 149:121–130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Patel V, Adya R, Chen J, Ramanjaneya M,
Bari MF, Bhudia SK, Hillhouse EW, Tan BK and Randeva HS: Novel
insights into the cardio-protective effects of FGF21 in lean and
obese rat hearts. PLoS One. 9:e871022014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Planavila A, Redondo I, Hondares E,
Vinciguerra M, Munts C, Iglesias R, Gabrielli LA, Sitges M, Giralt
M, van Bilsen M and Villarroya F: Fibroblast growth factor 21
protects against cardiac hypertrophy in mice. Nat Commun. 4:2019
06;2013. doi: 10.1038/ncomms3019.
|
|
42
|
Planavila A, Redondo-Angulo I and
Villarroya F: FGF21 and cardiac physiopathology. Front Endocrinol.
6:1332015. View Article : Google Scholar
|
|
43
|
Vahanian A and Iung B: The new ESC/EACTS
guidelines on the management of valvular heart disease. Arch
Cardiovasc Dis. 105:465–467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gisondi P, Lora V, Bonauguri C, Russo A,
Lippi G and Girolomoni G: Serum chemerin is increased in patients
with chronic plaque psoriasis and normalizes following treatment
with infliximab. Br J Dermatol. 168:749–755. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Herenius MMJ, Oliveira ASF, Wijbrandts CA,
Gerlag DM, Tak PP and Lebre MC: Anti-TNF therapy reduces serum
levels of chemerin in rheumatoid arthritis: A new mechanism by
which anti-TNF might reduce inflammation. PLoS One. 8:e578022013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Makrilakis K, Fragiadaki K, Smith J,
Sfikakis PP and Kitas GD: Interrelated reduction of chemerin and
plasminogen activator inhibitor-1 serum levels in rheumatoid
arthritis after interleukin-6 receptor blockade. Clin Rheumatol.
34:419–427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rutkowski P, Sledzinski T, Zielinska H,
Lizakowski S, Goyke E, Szrok-Wojtkiewicz S, Swierczynski J and
Rutkowski B: Decrease of serum chemerin concentration in patients
with end stage renal disease after successful kidney
transplantation. Regul Pept. 173:55–59. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Stepan H, Philipp A, Roth I, Kralisch S,
Jank A, Schaarschmidt W, Lössner U, Kratzsch J, Blüher M, Stumvoll
M, et al: Serum levels of the adipokine chemerin are increased in
preeclampsia during and 6 months after pregnancy. Regul Pept.
168:69–72. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Weigert J, Obermeier F, Neumeier M,
Wanninger J, Filarsky M, Bauer S, Aslanidis C, Rogler G, Ott C,
Schäffler A, et al: Circulating levels of chemerin and adiponectin
are higher in ulcerative colitis and chemerin is elevated in
Crohn's disease. Inflamm Bowel Dis. 16:630–637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xu QL, Zhu M, Jin Y, Wang N, Xu HX, Quan
LM, Wang SS and Li SS: The predictive value of the first-trimester
maternal serum chemerin level for pre-eclampsia. Peptides.
62:150–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang J, Jin HC, Zhu AK, Ying RC, Wei W
and Zhang FJ: Prognostic significance of plasma chemerin levels in
patients with gastric cancer. Peptides. 61:7–11. 2014. View Article : Google Scholar : PubMed/NCBI
|
